about
Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancerAndrogen Receptor: A Complex Therapeutic Target for Breast CancerPhenotypic diversity of breast cancer-related mutations in metalloproteinase-disintegrin ADAM12Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signalingBreast tumor specific mutation in GATA3 affects physiological mechanisms regulating transcription factor turnoverPower of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling indexDecreased expression of C10orf10 and its prognostic significance in human breast cancerBiological subtypes of breast cancer: Prognostic and therapeutic implications.Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers.Progesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective study.Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancerAcquired convergence of hormone signaling in breast cancer: ER and PR transition from functionally distinct in normal breast to predictors of metastatic disease.Profiling of alternative polyadenylation sites in luminal B breast cancer using the SAPAS method.Bone marrow stromal antigen 2 (BST-2) DNA is demethylated in breast tumors and breast cancer cells.The CCL2 chemokine is a negative regulator of autophagy and necrosis in luminal B breast cancer cellsThe Values of Combined and Sub-Stratified Imaging Scores with Ultrasonography and Mammography in Breast Cancer Subtypes.The Changing World of Breast Cancer: A Radiologist's Perspective.Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy.How interacting pathways are regulated by miRNAs in breast cancer subtypes.184AA3: a xenograft model of ER+ breast adenocarcinoma.Trastuzumab-Resistant Luminal B Breast Cancer Cells Show Basal-Like Cell Growth Features Through NF-κB-ActivationEffectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer.GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.Illuminating luminal B: QSOX1 as a subtype-specific biomarkerGene Expression Profiling of Breast Cancer Brain Metastasis.Prognostic value of the ubiquitin ligase carboxyl terminus of the Hsc70-interacting protein in postmenopausal breast cancer.High expression of ZNF703 independent of amplification indicates worse prognosis in patients with luminal B breast cancerERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization.Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients.Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profilingOestrogen receptor negativity in breast cancer: a cause or consequence?Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review).Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype.Luminal B breast cancer: patterns of recurrence and clinical outcome.Increased expression of mdig predicts poorer survival of the breast cancer patients.Advances in mechanisms of resistance to aromatase inhibitors.Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy.The olive oil phenolic (-)-oleocanthal modulates estrogen receptor expression in luminal breast cancer in vitro and in vivo and synergizes with tamoxifen treatment.Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: long-term outcomes in contemporary clinical practice.
P2860
Q27001260-93C8574C-CD57-4F3B-9C3D-302A5C9B0F96Q28075188-1DDB083F-1800-44B4-9369-07C84DEE837DQ30360467-8B8A6068-9205-4937-A0C0-866A33457754Q31132241-8EA52A69-983A-4511-9F12-D056F9D26E25Q33611408-48EF0B39-8B38-44E0-9B5D-D732DC021964Q33717341-C942CCA6-D05B-41DE-917C-22173D8F6A4EQ33768895-B8D7C841-D1AD-4938-92B7-773995EEFA98Q34023695-10F345B5-2946-4506-AC96-F13198F33988Q34034269-C4B8CD13-B3B4-4D0B-9CD8-6362E7BCCA7DQ34109691-9213654F-F4A9-410B-839B-69FBA463900AQ34243896-29C9A7A8-D16F-4560-9BAD-B053397230FBQ34483718-ACA154B6-1D01-4CC5-86BC-669165C3AEC4Q34599019-42A6CDBA-0CA9-476E-BEDE-DD6C5078F3A5Q35362935-603E6B05-ADE0-432B-AB2F-AB7BBB8D07DAQ35684572-4F783534-9304-4073-A9BF-6D2180E4436EQ35874075-EE359907-4F86-4E34-AEB9-07499A1A0D3DQ36217490-12FA289B-079B-4F3C-8520-96F9AFD1051BQ36228539-8C60D392-7584-4521-875D-C6EC83C8B3ABQ36276533-35F32192-734F-4ADC-BB17-D9F0BFCD2DF1Q36446649-70582201-539B-4094-9240-913147824321Q36630127-2EC19393-D865-45F9-96F5-489206DD67BEQ36917231-DC6F19F2-6E42-4063-9821-E545F84E02E3Q36940404-0FA352A0-4054-4EAF-BDED-BA28C84E22B3Q36998375-35A719BF-4DDE-431C-A260-CA28945F8534Q37034958-8A5E5CC3-E543-472B-BAAD-C974E66E611DQ37148939-43D39F1C-F62B-4CA6-879D-84EB7448050FQ37236234-01AA51B9-11A4-49EF-8C90-B44EB8E8B655Q37302065-90100FA3-0428-4D12-ADDE-88B130A01710Q37444430-B3014EF7-0F8B-463E-BC5B-33AEFCAD680CQ37458486-FB059D7B-0CF7-46A1-AB19-EF169F04B29AQ37529397-80C15E14-54DB-4D52-BDA7-F2842F17ED4BQ37554911-5B2C9710-7224-4DB8-9A7A-13875E6378ECQ37565213-877AB5C7-6286-4A7A-B1DE-6E66A3504D34Q37574493-9C54ECB8-E466-47B3-A750-97C87A804C1DQ37662184-611893BD-CB1C-4907-A208-08DD66E0B9E7Q37687043-4BF82473-A7AB-4101-8BA5-E4ABD49FCD4CQ38190106-006BEB57-9391-47A2-B10C-3000B0F7A075Q38213543-6723B45A-8798-4306-86D1-E1009CE277AAQ38699970-34D75D63-F45D-49A9-956F-AC49852DC0FCQ38896813-F3040AEE-E911-4BE4-974C-055A0E125039
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Luminal-B breast cancer and novel therapeutic targets.
@ast
Luminal-B breast cancer and novel therapeutic targets.
@en
type
label
Luminal-B breast cancer and novel therapeutic targets.
@ast
Luminal-B breast cancer and novel therapeutic targets.
@en
prefLabel
Luminal-B breast cancer and novel therapeutic targets.
@ast
Luminal-B breast cancer and novel therapeutic targets.
@en
P2860
P921
P356
P1476
Luminal-B breast cancer and novel therapeutic targets.
@en
P2093
P2860
P2888
P356
10.1186/BCR2904
P577
2011-11-30T00:00:00Z
P5875
P6179
1012506411